AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01754090 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online booklet.
Description: An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
Study NCT01754090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online multi session follow-up
Description: An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group).
Study NCT02217345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone
Description: growth hormone, Genotropin (Pfizer)
Study NCT02217345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo with identical drug pen delivery device and packaging as Genotropin (Pfizer)
Study NCT04058678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol/Placebo
Description: This group will be randomized 1:1 for either inactive substance or Danazol, according to a computer-generated randomization list prepared. Women will be treated with Danazol/Placebo oral way for 3 months.
Study NCT04058678 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Without intervention
Description: Women with normal ovarian reserve will not be treated in anyway, thus, randomization will not be necessary.
Study NCT02069834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1 (intervention)
Description: Dolutegravir 50 mg/j + Rilpivirine 25 mg/j qd orally (intake during meal)
Study NCT02069834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2 (control)
Description: Continuation of existing HAART at the time of randomization
Study NCT03208933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone 2403 mg/d capsules orally will be given in divided doses (TID) after titration period of 14 days.
Study NCT02305368 — intervention group
Intervention type: OTHER
Intervention: Chimio-oncogramme
Description: Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
Study NCT03405337 — intervention group
Intervention type: DRUG
Intervention: FVIII products
Description: Adynovate, Eloctate, Afstyla, Kovaltry
Study NCT03405337 — intervention group
Intervention type: DRUG
Intervention: Conventional FVIII replacement therapies
Description: Advate, Kogenate FS, Helixate, Novoeight, Nuwiq, Recombinate, Xyntha
Study NCT03447483 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patients starting a treatment by ICI
Description: Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30) before treatment administration and during the 12 months of treatment period, at the following time points:~* every 6 weeks for treatment regimen administered every 2 or 3 weeks~* at Weeks 6, 12, 20, 24 for treatment regimen administered every 4 weeks
Study NCT03520621 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: no intervention
Study NCT03207360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills
Description: Participants will be trained in pain coping skills and meaning-centered psychotherapy. The intervention will consist of 4 weekly videoconference-delivered sessions that will last between 45 and 60 minutes.
Study NCT04394910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate Juice
Study NCT04394910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Juice
Study NCT00410215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: picosalax plus bisacodyl
Description: 10 mg bisacodyl three and two nights prior to colonoscopy, followed by two sachets picosalax
Study NCT00410215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: picosalax
Description: two sachets of picosalax taken orally the day prior to colonoscopy
Study NCT02446912 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses
Study NCT00410215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium phosphate
Description: two 45 ml bottles of sodium phosphate the day prior to colonoscopy
Study NCT01286337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bipolar vessel sealing
Study NCT01286337 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control
Study NCT02268045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTXM83
Description: Rituximab biosimilar (RTXM83) will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
Study NCT02268045 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mabthera
Description: Mabthera will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
Study NCT00149669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: employment-based reinforcement
Description: Work Plus Naltrexone Contingency participants were required to ingest naltrexone to work, and received a brief pay decrease for missing a dose.
Study NCT02033577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal gastrojejunal bypass
Description: RYGB with 200 cm BP limb and 150 cm common limb, effect on EWL, QoL and complications
Study NCT02033577 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RYGB
Description: RYGB with 60 cm BP limb and 150 cm alimentary limb, effect on
Study NCT01822015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT01822015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV
Study NCT01822015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02766088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: All participants will have an enrolment visit with collection of a blood sample and a termination contact/visit. Participants or their parents/guardians will be contacted weekly or every two weeks to monitor the occurrence of febrile episodes. Additional visits will be made if febrile episodes occur. In case of dengue suspicion, a blood sample will be collected.
Study NCT00860574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treosulfan
Description: Given IV
Study NCT00860574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00860574 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Low dose starting at 2Gy
Study NCT00860574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Given IV per institutional standard practice
Study NCT00860574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or PO
Study NCT00860574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Given IV per institutional standard practice
Study NCT00860574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Given IV per institutional standard practice
Study NCT00860574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT00673322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene Modified T Cells
Description: One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
Study NCT03320473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IC-8 IOL
Description: The AcuFocus IC-8 intraocular lens (IC-8 IOL) is a one-piece hydrophobic acrylic posterior chamber IOL into which a circular mask with a small 1.36 mm central aperture has been embedded. The IOL mask works by extending the depth of focus and its design is based on the KAMRA corneal inlay, which operates under the principle of small aperture optics.
Study NCT04948255 — intervention group
Intervention type: OTHER
Intervention: Health and Safety Executive's (HSE) Management Standards Indicator Tool (MSIT) to measure work-related stress
Description: Questionnaire
Study NCT01354262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 600 IU daily oral supplementation
Study NCT01354262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 50,000 IU supplementation bi-monthly
Study NCT03039374 — intervention group
Intervention type: OTHER
Intervention: Magnetic resonance imaging
Description: The extent of obstetric anal sphincter injury will be evaluated using MRI, endoanal ultrasound and anal manometry
Study NCT03312582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% local metformin gel
Description: After providing manual debridement in deep peri-implant probing depths, 1% metformin gel will be applied.
Study NCT03312582 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02639819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ɛ-Aminocaproic Acid
Description: Intervention: intravenous ε-Aminocaproic Acid within 3 hours of symptom onset
Study NCT02446912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV administration every 4 weeks from Week 0 to Week 48
Study NCT01357031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: It will be administered Amitriptyline (25mg) once a day at bed time. Patients may keep their abortive treatment that they usually used. The drug will be encapsulated in a bottle of 30 capsules will be given to patients at every visit.
Study NCT01357031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: It will be administered Melatonin (3mg) at bed time, half an hour before the usual time of sleep of the patient.
Study NCT01357031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It will be administered placebo capsules, identical to Melatonin (3mg) and Amitriptyline (25 mg) patients will take the study medication at bed time
Study NCT02118701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Decision-Making educational training
Study NCT02795130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sclerotomy closure
Description: Comparison between two suture materials: 1) 8-0 polyglactin 910, 2) 6-0 plain gut
Study NCT00879424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol (vitamin D)
Description: 1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops.
Study NCT00879424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops.
Study NCT00595049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: Bosentan 62.5 mg bid for 4 weeks, then 125 mg bid
Study NCT03719729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Administer daily rifaximin to modify intestinal microbiome to alter the course of the disease.
Study NCT01340365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Exercise
Description: Practicing Tai Chi exercise 4 times a week for 6 months - twice in a classroom and twice independently
Study NCT01340365 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tai Chi
Description: Usual care, individuals attend testing sessions for 6 months with testing at times 0, 3, and 6 months. Individuals in Usual Care receive 3 months of Tai Chi at the study end.
Study NCT02247505 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Harnal-D Cap. 0.2mg
Study NCT02247505 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cialis Tab. 5mg
Study NCT01332877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enriched breakfast
Description: high carbohydrate, high protein breakfast supplying 600 kcal as 50k% carbohydrate, 20% protein, 30% fat
Study NCT01332877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control breakfast
Description: Control breakfast providing 300 kcal, 13% carbohydrate, 40% protein, 48% fat
Study NCT02105948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
Study NCT01827202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RAS blockade discontinuation
Description: In the initial two weeks of the study, all RAS blockade will be eliminated from the subjects' antihypertensive regimen
Study NCT01827202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Study NCT01827202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Study NCT02270606 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT
Study NCT02105948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile 0.9% sodium chloride solution
Study NCT02270606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT02270606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT04644432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication (A specification is listed under each arm)
Description: Study drugs and dosages are listed in the description of arms.
Study NCT04644432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient reported outcomes measurement
Description: PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events.~The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital.~For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish.
Study NCT02702830 — intervention group
Intervention type: OTHER
Intervention: Cardiopulmonary Exercise Testing
Description: Undergo CPET
Study NCT00328042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management Workshop
Description: The workshop is a once per week 2.5 hour group that meets for six weeks.
Study NCT00328042 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Only
Description: This is an individual self-paced at home study program.
Study NCT03552354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban plus dual antiplatelet
Description: A continuous argatroban infusion of 1.0 ug/kg per minute for 2-5 days adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%). For the first day, clopidogrel with loading dose 300mg, and aspirin 100mg were given, and followed by clopidogrel 75 mg and aspirin 100mg each day
Study NCT02702830 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03416205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erbao electric knife
Description: Erbao electric knife is used to cut the Duodenal sphincter
Study NCT03416205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three-cavity incision knife
Description: Three-cavity incision knife is used to cut the Duodenal sphincter
Study NCT03416205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Columnar expansion balloon
Description: Columnar expansion balloon is used to expand the the Duodenal sphincter
Study NCT03823365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab Expanded T-cells (BET)
Description: Two to five days after the last chemotherapy infusion, BET will be administered. An accelerated titration dose escalation design will be used. During dose escalation, up to four dose levels (see table) will be evaluated or until (Maximum Tolerated Dose) MTD is reached.~Dose level BET dose(Counted on CD3+ cells)~1. (starting dose) 3.0 x 109~2. 6.0 x 109~3. 9.0 x 109~4. 12.0 x 109
Study NCT00350519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Description: Participants will receive epoetin alfa 300 IU/kg once daily subcutaneously for 10 days prior to surgery, on the day of surgery, and for four days after surgery.
Study NCT00350519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants will receive standard of care based on the Institution's treatment policy.
Study NCT02358954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing
Description: Measurement of warm and cold detection and pain thresholds
Study NCT02358954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CHEPS
Description: Measurement of amplitude and latency of cortically evoked potentials
Study NCT02358954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Turntable
Study NCT02358954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vection stimulation
Study NCT00659854 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non milk or soy based formula
Description: Babies will be given a non milk or soy base formula for 12 weeks
Study NCT00659854 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: milk based formula
Description: Babies will be given a milk based formula for 12 weeks
Study NCT03670537 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Iron parameters
Description: Serum iron, total iron binding capacity, TSAT (Fe/TIBC), serum ferritin
Study NCT00651547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol
Study NCT00651547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Study NCT00651547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol
Study NCT04862104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: In addition to the routine care they received, the patients in the intervention groups were given discharge training developed in the pre-discharge period. Discharge training consisted of a verbal and written information booklet containing instructions for the patient and the patient's caregiver on pain management, nutrition management, incision site care, strengthening self-care, returning to daily life activities, and colostomy care. Discharge training was given in the service after evaluating the surgical recovery status of the patient before discharge. The average duration of each training was 30-45 minutes. The patients were evaluated in terms of surgical recovery by calling by phone 2 weeks after discharge, 4 weeks and 8 weeks later. The developed education booklet was given to the patient and it was ensured that he could benefit from the information at home.
Study NCT00158327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based collaborative care
Description: Participants assigned to the telephone-based program will have a choice of what type of treatment they will receive. The choices will include pharmacotherapy, workbook training designed to help participants improve their coping skills, referral to a community mental health specialist, or some combination of these treatments. Participants will receive telephone calls one to two times every month for 12 months. During the calls, participants will be asked about their attitude toward and adherence to their treatment regimen. They will also be asked about recent episodes of anxiety they have experienced and what coping techniques they have used.
Study NCT00158327 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care may include one or more of several different treatments such as pharmacotherapy and cognitive behavioral therapy; the treatments will be chosen by participants' physicians and will be delivered for 12 months.